Table of Contents
The company behind the world’s first effective urine-based screening test for prostate cancer is looking to raise money to expand.
Cambridge-based Oncologica has hired corporate advisory firm FRP Corporate Finance to raise £6m of potential investors.
The funds will be used to complete clinical trials and obtain regulatory approval for its “revolutionary” early detection technology.
Prostate cancer is the most common cancer in men in the UK – around one in eight are diagnosed during their lifetime.
It mainly affects men over 50 years of age, the risk increases with age, and is responsible for 12,000 deaths each year.
Expansion plans: Cambridge-based Oncologica has hired business advisory firm FRP Advisory to attract potential investors for £6m
Currently, tests to detect prostate cancer include a prostate-specific antigen (PSA) blood test, imaging scans, and a sample or biopsy of the prostate gland.
But blood tests or scans alone cannot determine for sure whether someone has prostate cancer.
A biopsy is more reliable but can also detect small, low-risk cancers that do not need treatment.
Oncologica has developed urine tests that distinguish between aggressive prostate cancers and harmless ones that do not require treatment.
Dr Marco Loddo, co-founder and chief scientific officer, said: “This precision ensures that men are not subjected to unnecessary, costly and invasive procedures.”
Co-founder and medical director Professor Gareth Williams added: “Our urine test will revolutionise early detection rates and patient outcomes.”
Dan Bowtell, a partner at FRP, said the innovation was “a shining example of the UK’s status as a global life sciences superpower”.
DIY INVESTMENT PLATFORMS
AJ Bell
AJ Bell
Easy investment and ready-to-use portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free investment ideas and fund trading
interactive investor
interactive investor
Flat rate investing from £4.99 per month
Saxo
Saxo
Get £200 back in trading commissions
Trade 212
Trade 212
Free treatment and no commissions per account
Affiliate links: If you purchase a product This is Money may earn a commission. These offers are chosen by our editorial team as we believe they are worth highlighting. This does not affect our editorial independence.